Growing community of inventors

Boulogne Billancourt, France

Xavier Guillonneau

Average Co-Inventor Count = 4.61

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 1

Xavier GuillonneauJose-Alain Sahel (4 patents)Xavier GuillonneauFlorian Sennlaub (4 patents)Xavier GuillonneauPhilippe Karoyan (1 patent)Xavier GuillonneauOlivier Levy (1 patent)Xavier GuillonneauFadoua Montassar (1 patent)Xavier GuillonneauNaziha Marrakchi (1 patent)Xavier GuillonneauErij Messadi (1 patent)Xavier GuillonneauMichael Housset (1 patent)Xavier GuillonneauBertrand Callippe (1 patent)Xavier GuillonneauJosé-Alain Sahel (0 patent)Xavier GuillonneauXavier Guillonneau (4 patents)Jose-Alain SahelJose-Alain Sahel (44 patents)Florian SennlaubFlorian Sennlaub (10 patents)Philippe KaroyanPhilippe Karoyan (5 patents)Olivier LevyOlivier Levy (5 patents)Fadoua MontassarFadoua Montassar (1 patent)Naziha MarrakchiNaziha Marrakchi (1 patent)Erij MessadiErij Messadi (1 patent)Michael HoussetMichael Housset (1 patent)Bertrand CallippeBertrand Callippe (1 patent)José-Alain SahelJosé-Alain Sahel (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Centre National De La Recherche Scientifique (4 from 5,072 patents)

2. Institut National De La Sante Et De La Recherche Medicale (3 from 1,743 patents)

3. Sorbonne Université (3 from 236 patents)

4. Institut Pasteur De Tunis (1 from 6 patents)

5. Sarbonne IniversiÉ (1 from 1 patent)

6. Inserm (institut National De La Sante Et De La Recherche Medicale) (37 patents)

7. Inserm (0 patent)


4 patents:

1. 11191807 - Lebecetin, a C-type lectin, as neovascularization inhibitor

2. 11142548 - Agents that activate CD47 and their use in the treatment of inflammation

3. 11072661 - Agents that inhibit the binding of CFH to CD11 b/CD18 and uses thereof

4. 10519232 - Agents for use in the treatment of retinal inflammation

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/12/2025
Loading…